https://nsc127716inhibitor.com..../wide-spread-and-loc
Objective To compare the efficacy and protection of olaparib in combination with pembrolizumab with pembrolizumab alone in second-line treatment for patients with extensive stage-small cellular lung cancer tumors (ES-SCLC) whose ages ranged from 40 to 80 years. Methods From March 2017 to October 2019, 21 clients with progressed or relapsed small mobile lung cancer after standard first-line therapy had been signed up for this research. The olaparib/pembrolizumab group (n=11)
Like
Comment
Share
